REGENXBIO Current Ratio 2014-2022 | RGNX
REGENXBIO current ratio from 2014 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| REGENXBIO Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2022-09-30 |
$0.44B |
$0.12B |
3.53 |
| 2022-06-30 |
$0.47B |
$0.12B |
4.06 |
| 2022-03-31 |
$0.45B |
$0.12B |
3.73 |
| 2021-12-31 |
$0.52B |
$0.13B |
3.98 |
| 2021-09-30 |
$0.41B |
$0.11B |
3.84 |
| 2021-06-30 |
$0.44B |
$0.09B |
4.78 |
| 2021-03-31 |
$0.50B |
$0.08B |
5.94 |
| 2020-12-31 |
$0.53B |
$0.08B |
6.52 |
| 2020-09-30 |
$0.39B |
$0.06B |
6.08 |
| 2020-06-30 |
$0.33B |
$0.04B |
8.19 |
| 2020-03-31 |
$0.34B |
$0.03B |
10.64 |
| 2019-12-31 |
$0.35B |
$0.03B |
10.25 |
| 2019-09-30 |
$0.36B |
$0.03B |
11.49 |
| 2019-06-30 |
$0.36B |
$0.03B |
14.58 |
| 2019-03-31 |
$0.30B |
$0.02B |
14.21 |
| 2018-12-31 |
$0.34B |
$0.02B |
15.24 |
| 2018-09-30 |
$0.39B |
$0.02B |
20.21 |
| 2018-06-30 |
$0.29B |
$0.02B |
17.40 |
| 2018-03-31 |
$0.26B |
$0.02B |
17.66 |
| 2017-12-31 |
$0.17B |
$0.01B |
11.64 |
| 2017-09-30 |
$0.17B |
$0.01B |
12.85 |
| 2017-06-30 |
$0.17B |
$0.01B |
14.47 |
| 2017-03-31 |
$0.15B |
$0.01B |
14.94 |
| 2016-12-31 |
$0.09B |
$0.01B |
9.66 |
| 2016-09-30 |
$0.10B |
$0.01B |
6.72 |
| 2016-06-30 |
$0.10B |
$0.01B |
10.70 |
| 2016-03-31 |
$0.11B |
$0.01B |
18.26 |
| 2015-12-31 |
$0.12B |
$0.00B |
27.23 |
| 2015-09-30 |
$0.22B |
$0.01B |
40.60 |
| 2015-06-30 |
$0.00B |
|
0.00 |
| 2015-03-31 |
$0.00B |
|
0.00 |
| 2014-12-31 |
$0.00B |
|
0.00 |
| 2014-09-30 |
$0.00B |
|
0.00 |
| 2013-12-31 |
$0.00B |
$0.01B |
0.47 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.972B |
$0.470B |
|
REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.
|
